Depression in Psoriatic Arthritis: Dimensional Aspects and Link with Systemic Inflammation
Open accessThe DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Abstract
Studying comorbidities in patients with psoriatic arthritis (PsA) provides a better understanding of the extended burden of the disease. Depression and anxiety are well recognized but understudied comorbidities in patients with PsA. The prevalence of depression is significantly higher in this patient population than in the general population, with far reaching consequences in terms of long-term quality of life. Over the past few years there has been an increasing interest in the link between inflammation and depression, with several novel studies being conducted. Recent evidence suggests a significant improvement of depression in PsA patients treated with biologic disease-modifying anti-rheumatic drugs (bDMARDs) as compared to conventional DMARDs. Depression in PsA is multidimensional, with recognized phenotypes, including cognitive disorder, alexithymia and anhedonia. The paucity of standardized, validated tools to screen these dimensional phenotypes remains an unmet need. Prevalence studies on depression in patients with PsA, mostly based on patient-reported outcomes, are only able to highlight the tip of the iceberg. A comprehensive, multi-disciplinary approach addressing the subdomains of depression is imperative for a better understanding of depression in PsA patients, as well as to find a way forward for improving their quality of life. In this scoping review, we explore existing evidence on the burden of depression in PsA patients, the link between inflammation and depression in these patients and the screening tools used to evaluate the subdomains of depression. Psoriatic arthritis (PsA) is a chronic, deforming arthritis associated with the skin condition psoriasis. A large number of patients with PsA are known to have another co-existing chronic disease, which adds to their overall disease burden and affects their quality of life. Depression is a common illness known to co-exist in about 20% of patients with PsA. Inflammation is a common factor between psoriatic arthritis and depressive disorders and is thought to play an important role in depression ocurring in these patients. Recent research in the field has revealed that different dimensions of depression, such as the inability to feel pleasure, loss of intellectual functions and difficulty identifying and expressing emotions, may contribute to the overall disease. It is important to screen for these dimensions while assessing PsA patients with depression. Most of the studies conducted to date have based the diagnosis of depression on self-reported questionnaires. In this article we describe the relation between inflammation and different dimensions of depression in patients with PsA and set out a feasible screening method for depression. A good understanding of depression in patients with PsA will be useful in designing treatment strategies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Rush, A. J., Trivedi, M. H., Ibrahim, H. M., Carmody, T. J., Arnow, B., Klein, D. N., Markowitz, J. C., Ninan, P. T., Kornstein, S., Manber, R., et al. (2003) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01866-8 · Cited by 3,829
Depression and Pain Comorbidity: A Literature Review
Bair, M. J., Robinson, R. L., Katon, W., & Kroenke, K. (2003) · Archives of Internal Medicine · doi:10.1001/archinte.163.20.2433 · Cited by 3,463
Cytokines sing the blues: inflammation and the pathogenesis of depression
Raison, C. L., Capuron, L., & Miller, A. H. (2006) · Trends in Immunology · doi:10.1016/j.it.2005.11.006 · Cited by 3,009
A scale for the assessment of hedonic tone the Snaith-Hamilton pleasure scale
Snaith, R. P., Hamilton, M., Morley, S., Humayan, A., Hargreaves, D., & Trigwell, P. (1995) · British Journal of Psychiatry · doi:10.1192/bjp.167.1.99 · Cited by 1,778
Hippocampal Volume Reduction in Major Depression
Bremner, J. D., Narayan, M., Anderson, E. R., Staib, L. H., Miller, H. L., & Charney, D. S. (2000) · American Journal of Psychiatry · doi:10.1176/ajp.157.1.115 · Cited by 1,670
Raison, C. L., Rutherford, R. E., Woolwine, B. J., Shuo, C., Schettler, P., Drake, D. F., Haroon, E., & Miller, A. H. (2013) · JAMA Psychiatry · doi:10.1001/2013.jamapsychiatry.4 · Cited by 1,617
The role of corticotropin-releasing factor in depression and anxiety disorders
Arborelius, L., Owens, M., Plotsky, P., & Nemeroff, C. (1999) · Journal of Endocrinology · doi:10.1677/joe.0.1600001 · Cited by 1,378
Sheline, Y. I., Price, J. L., Yan, Z., & Mintun, M. A. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1000446107 · Cited by 1,196
Hannestad, J., DellaGioia, N., & Bloch, M. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.132 · Cited by 914
Hasler, G., van der Veen, J. W., Tumonis, T., Meyers, N., Shen, J., & Drevets, W. C. (2007) · Archives of General Psychiatry · doi:10.1001/archpsyc.64.2.193 · Cited by 846
Major depressive disorder and hypothalamic-pituitary-adrenal axis activity
Vreeburg, S. A., Hoogendijk, W. J. G., van Pelt, J., DeRijk, R. H., Verhagen, J. C. M., van Dyck, R., Smit, J. H., Zitman, F. G., & Penninx, B. W. J. H. (2009) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2009.50 · Cited by 792
Zhu, X., Wang, X., Xiao, J., Liao, J., Zhong, M., Wang, W., & Yao, S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.10.035 · Cited by 638
Pain, catastrophizing, and depression in the rheumatic diseases
Edwards, R. R., Cahalan, C., Mensing, G., Smith, M., & Haythornthwaite, J. A. (2011) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2011.2 · Cited by 596
Uher, R., Perlis, R. H., Henigsberg, N., Zobel, A., Rietschel, M., Mors, O., Hauser, J., Dernovsek, M. Z., Souery, D., Bajs, M., et al. (2012) · Psychological Medicine · doi:10.1017/s0033291711001905 · Cited by 420
Franken, I. H. A., Rassin, E., & Muris, P. (2007) · Journal of Affective Disorders · doi:10.1016/j.jad.2006.08.020 · Cited by 373
Li, S., Zhang, B., Guo, Y., & Zhang, J. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.02.006 · Cited by 341
Depression and anxiety in psoriatic disease: prevalence and associated factors
McDonough, E., Ayearst, R., Eder, L., Chandran, V., Rosen, C. F., Thavaneswaran, A., & Gladman, D. D. (2014) · The Journal of Rheumatology · doi:10.3899/jrheum.130797 · Cited by 250 · cited 1×
“…2017 CS [40] Gladman 2014 RCT [57] Hospital Anxiety and Depression scale (HADS) Gniadecki 2011 RCT [58] Freire 2011 CS [13] Bandinelli 2013 CS [10] McDonough 2014 CS [11] Meesters 2014 CS [59] Howells 2018 CS [60] Strober 2018 CS [61] Patient Health Questionnaire 9-item scale (PHQ-9) Kotsis 2012…”
BackgroundCognitive dysfunction in major depressive disorder
Knight, M. J., & Baune, B. T. (2018) · Current Opinion in Psychiatry · doi:10.1097/yco.0000000000000378 · Cited by 207
Placebo effect in the treatment of depression and anxiety
Kirsch, I. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00407 · Cited by 205
McIntyre, R. S., Subramaniapillai, M., Lee, Y., Pan, Z., Carmona, N. E., Shekotikhina, M., Rosenblat, J. D., Brietzke, E., Soczynska, J. K., Cosgrove, V. E., et al. (2019) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2019.0779 · Cited by 200
Psychiatric adverse events during treatment with brodalumab: Analysis of psoriasis clinical trials
Lebwohl, M. G., Papp, K. A., Marangell, L. B., Koo, J., Blauvelt, A., Gooderham, M., Wu, J. J., Rastogi, S., Harris, S., Pillai, R., et al. (2018) · Journal of the American Academy of Dermatology · doi:10.1016/j.jaad.2017.08.024 · Cited by 179
McIntyre, R. S., Best, M. W., Bowie, C. R., Carmona, N. E., Cha, D. S., Lee, Y., Subramaniapillai, M., Mansur, R. B., Barry, H., Baune, B. T., et al. (2017) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.16m11329 · Cited by 172
Hemming, L., Haddock, G., Shaw, J., & Pratt, D. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00203 · Cited by 170
The Multifaceted Nature of Alexithymia – A Neuroscientific Perspective
Goerlich, K. S. (2018) · Frontiers in Psychology · doi:10.3389/fpsyg.2018.01614 · Cited by 170
Bortolato, B., F. Carvalho, A., K. Soczynska, J., I. Perini, G., & S. McIntyre, R. (2015) · Current Neuropharmacology · doi:10.2174/1570159x13666150630171433 · Cited by 142
Ott, C. V., Bjertrup, A. J., Jensen, J. H., Ullum, H., Sjælland, R., Purdon, S. E., Vieta, E., Kessing, L. V., & Miskowiak, K. W. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.10.059 · Cited by 128
Kim, J.-W., Kim, Y.-K., Hwang, J.-A., Yoon, H.-K., Ko, Y.-H., Han, C., Lee, H.-J., Ham, B.-J., & Lee, H. S. (2013) · Psychiatry Investigation · doi:10.4306/pi.2013.10.3.294 · Cited by 77
McIntyre, R. S., Woldeyohannes, H. O., Soczynska, J. K., Maruschak, N. A., Wium-Andersen, I. K., Vinberg, M., Cha, D. S., Lee, Y., Xiao, H. X., Gallaugher, L. A., et al. (2016) · CNS Spectrums · doi:10.1017/s1092852915000747 · Cited by 56
Inflammatory Biomarkers in Depression: An Opportunity for Novel Therapeutic Interventions
Li, M., Soczynska, J. K., & Kennedy, S. H. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-011-0210-6 · Cited by 53
Keeping up with the clinical advances: depression
Ragguett, R.-M., Tamura, J. K., & McIntyre, R. S. (2019) · CNS Spectrums · doi:10.1017/s1092852919001159 · Cited by 27 · cited 1×
“This will guide therapeutic decisions as the subdomains of depression may respond differentially to treatment [80, 81].”
Background
Cited by
Berry, S. P. D.-G., Dossou, C., Kashif, A., Sharifinejad, N., Azizi, G., Hamedifar, H., Sabzvari, A., & Zian, Z. (2022) · International Immunopharmacology · doi:10.1016/j.intimp.2021.108402 · Cited by 124
Th17 cells and inflammation in neurological disorders: Possible mechanisms of action
Shi, Y., Wei, B., Li, L., Wang, B., & Sun, M. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.932152 · Cited by 108
Gałecka, M., Bliźniewska-Kowalska, K., Orzechowska, A., Szemraj, J., Maes, M., Berk, M., Su, K.-P., & Gałecki, P. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11020066 · Cited by 57
“This may be related to the general improvement of the clinical condition and reduction of symptoms in this group of patients, but also to the possible common inflammatory background of depression and autoimmune diseases [23].”
Background
Metadata
- Authors
- Mathew, A. J., & Chandran, V.
- Venue
- Rheumatology and Therapy
- Published
- 2020-04-22
- Volume
- 7
- Issue
- 2
- Pages
- 287-300
- ISSN
- 2198-6576 (ISSN-L)
- 2198-6584
- OpenAlex
- W3019766834
- Cited by
- 60
- References
- 30
- FWCI
- 4.29
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.